By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


REGENX Biosciences, LLC 

750 17th St. NW, Suite 1100

Washington  D.C.   20006  U.S.A.
Phone: 202-785-7438 Fax:


Company News
REGENXBIO Reports Third Quarter 2015 Results 11/5/2015 10:18:49 AM
Dr. David C. Stump Appointed To REGENXBIO Board Of Directors 10/15/2015 7:43:39 AM
FDA Grants Orphan Drug Designation To REGENXBIO's RGX-111 Gene Therapy For The Treatment Of Mucopolysaccharidosis Type I (MPS I) 10/2/2015 7:45:03 AM
REGENXBIO Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares 9/23/2015 7:20:08 AM
REGENXBIO Takes Center Stage With $139M IPO 9/17/2015 5:54:49 AM
Gene Therapy Biotech REGENXBIO Increases Proposed IPO Price To $22 9/16/2015 11:52:13 AM
Nabriva, REGENXBIO, and Penumbra Set to Go Public This Week 9/14/2015 9:27:08 AM
REGENXBIO Files for $100 Milllion IPO 8/18/2015 7:46:19 AM
REGENXBIO Enters Into Strategic Manufacturing Collaboration With WuXi AppTec, Inc. 6/11/2015 7:25:21 AM
Dr. Jerry Karabelas Appointed To REGENXBIO Board Of Directors 5/27/2015 7:20:34 AM